CA3004908A1 - B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components - Google Patents

B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components Download PDF

Info

Publication number
CA3004908A1
CA3004908A1 CA3004908A CA3004908A CA3004908A1 CA 3004908 A1 CA3004908 A1 CA 3004908A1 CA 3004908 A CA3004908 A CA 3004908A CA 3004908 A CA3004908 A CA 3004908A CA 3004908 A1 CA3004908 A1 CA 3004908A1
Authority
CA
Canada
Prior art keywords
seq
fibril
lymphocytes
cells
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3004908A
Other languages
English (en)
French (fr)
Inventor
Lawrence Steinman
Michael KURNELLAS
Jonathan Rothbard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA3004908A1 publication Critical patent/CA3004908A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3004908A 2015-11-18 2016-11-18 B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components Abandoned CA3004908A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562256814P 2015-11-18 2015-11-18
US62/256,814 2015-11-18
PCT/US2016/062878 WO2017087868A2 (en) 2015-11-18 2016-11-18 B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components

Publications (1)

Publication Number Publication Date
CA3004908A1 true CA3004908A1 (en) 2017-05-26

Family

ID=58717881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3004908A Abandoned CA3004908A1 (en) 2015-11-18 2016-11-18 B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components

Country Status (6)

Country Link
US (2) US20180333451A1 (de)
EP (2) EP3858440A3 (de)
JP (1) JP2018534330A (de)
CA (1) CA3004908A1 (de)
ES (1) ES2862700T3 (de)
WO (1) WO2017087868A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018105656A1 (de) 2017-12-11 2019-06-13 Klemens Dittrich Ladestation für Telekommunikationsgeräte, insbesondere für kabellose Ladegeräte

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
EA016072B1 (ru) * 2005-05-18 2012-01-30 Палметрикс Инк. Применение состава соли кальция для изменения биофизических свойств слизистой оболочки
US8257685B2 (en) * 2006-04-04 2012-09-04 Stc.Unm Swellable particles for drug delivery
EP2061446A2 (de) * 2006-07-28 2009-05-27 University Court of the University of Edinburgh Verwendung von cdk-hemmern zur behandlung von granulozyten-vermittelten erkrankungen
AU2011305330B2 (en) * 2010-09-22 2015-04-16 The Feinstein Institute For Medical Research Human B1 cells and uses thereof

Also Published As

Publication number Publication date
WO2017087868A2 (en) 2017-05-26
US20180333451A1 (en) 2018-11-22
WO2017087868A3 (en) 2017-07-13
EP3858440A2 (de) 2021-08-04
EP3377178B1 (de) 2021-01-06
JP2018534330A (ja) 2018-11-22
EP3377178A4 (de) 2019-10-09
US20200000871A1 (en) 2020-01-02
EP3858440A3 (de) 2021-11-03
EP3377178A2 (de) 2018-09-26
ES2862700T3 (es) 2021-10-07

Similar Documents

Publication Publication Date Title
AU2016377681B2 (en) Compounds and compositions for intracellular delivery of agents
US20180085474A1 (en) Lipid nanoparticle compositions
US9127040B2 (en) Regulation of sodium channels by PLUNC proteins
WO2016118724A1 (en) Lipid nanoparticle compositions
Lawrence et al. Role of VASP in reestablishment of epithelial tight junction assembly after Ca2+ switch
JP6033781B2 (ja) 低分子ペプチド阻害剤によるＣＤ４０Ｌ／Ｍａｃ−１相互作用の選択的ターゲティングならびに炎症およびアテローム形成の治療のためのその使用
Khan et al. Acanthamoeba affects the integrity of human brain microvascular endothelial cells and degrades the tight junction proteins
ES2784234T3 (es) Métodos para el tratamiento de cánceres fibróticos
ES2559029T3 (es) Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
Ratajczak et al. The role of innate immunity in trafficking of hematopoietic stem cells—an emerging link between activation of complement cascade and chemotactic gradients of bioactive sphingolipids
US9592268B2 (en) Endothelium protective materials and methods of use
JP7048608B2 (ja) Ａｐｏｍ－ｆｃ融合タンパク質、それとスフィンゴシン１－リン酸（ｓ１ｐ）との複合体、および血管疾患および非血管疾患を処置するための方法
JP2022518262A (ja) ナチュラルキラー細胞を刺激するための組成物及び方法
ES2895256T3 (es) Polipéptidos para inhibir la activación del complemento
US9549967B2 (en) Regulation of sodium channels by PLUNC proteins
Crobu et al. Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®
US20200000871A1 (en) B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components
JP7236134B2 (ja) 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
TWI609692B (zh) 新穎ｓｔｉｐ１多肽及其用途
CA2883447A1 (en) Therapeutic compositions and related methods
RU2711161C2 (ru) Циклический с-концевой пептид ацетилхолинэстеразы в лечении или предупреждении рака или метастазирования
KR102191695B1 (ko) 전이 억제제
US10450349B2 (en) Multivalent fibronectin-integrin binding compositions and methods of use thereof
Kumar et al. Peptides with antifungal activity and methods of using the peptides
Włoga Session 3. Cytoskeleton, Intracellular Transport and Cell Motility

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831